Newleos Therapeutics

Newleos Therapeutics is dedicated to bringing a new dawn, or “eos,” to patients with mental health issues by developing next-generation, first-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders representing the largest areas of unmet medical need. The company’s clinical-stage pipeline, licensed from Roche, includes orally administered small molecules targeting GABA—one-γ1, V1a, TAAR1, and GABA—one-α5—showing broad potential in generalized anxiety, social anxiety, substance use disorders, and cognitive impairment.